FGFR2 Antibody (133706) [Unconjugated] - (IIIc)

Recombinant Mouse FGF R2 beta (IIIc) Fc Chimera (Catalog # 716-MF) inhibits Recombinant Human FGF acidic (Catalog # 232-FA) induced proliferation in the NR6R‑3T3 mouse fibroblast cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human FGF acidic (0.3 ng/mL) activity elicited by Recombinant Mouse FGF R2 beta (IIIc) Fc Chimera (3 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse FGF R2 (IIIc) Monoclonal Antibody (Catalog # MAB716). The ND50 is typically 0.1-0.4 µg/mL in the presence of heparin (10 µg/mL).

• Reactivity: Mu
• Applications: WB, B/N
• Clone: 133706
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

FGFR2 Antibody (133706) [Unconjugated] - (IIIc) Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse FGF R2 alpha (IIIc)
  Extracellular domains
• Specificity: Detects IIIc isoforms of mouse FGF R2 in direct ELISAs and Western blots. Does not react with IIIb isoforms of recombinant mouse (rm) FGF R2. In direct ELISAs and Western blots, 100% cross-reactivity with IIIc isoforms of recombinant human (rh) FGF R2 is observed, and no cross-reactivity with IIIb isoforms of rhFGF R2 or any isoforms of rhFGF R1, rmFGF R3, or rhFGF R4 is observed.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: FGFR2
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Western Blot 1 ug/mL
  • Neutralization 0.1-0.4 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FGFR2 Antibody (133706) [Unconjugated] - (IIIc)

• BBDS
• BEK
• BFR-1
• CD332 antigen
• CD332
• CEK3
• CFD1
• craniofacial dysostosis 1
• EC 2.7.10
• EC 2.7.10.1
• ECT1
• FGF R2
• FGFR2
• fibroblast growth factor receptor 2
• FLJ98662
• Jackson-Weiss syndrome
• JWS
• Keratinocyte growth factor receptorreceptor like 14
• KGFR
• KSAM
• K-sam
• soluble FGFR4 variant 4
• TK14
• TK25

Background

Fibroblast growth factors (FGFs) comprise a family of at least eighteen structurally related proteins that are involved in a multitude of physiological and pathological cellular processes, including cell growth, differentiation, angiogenesis, wound healing and tumorigenesis. The biological activities of the FGFs are mediated by a family of type I transmembrane tyrosine kinases which undergo dimerization and autophosphorylation after ligand binding. Four distinct genes encoding closely related FGF receptors, FGF R1‑4, are known. All four genes for FGF Rs encode proteins with an N-terminal signal peptide, three immunoglobulin (Ig)-like domains, an acid‑box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain. Multiple forms of FGF R1‑3 are generated by alternative splicing of the mRNAs. A frequent splicing event involving FGF R1 and 2 results in receptors containing all three Ig domains, referred to as the alpha  isoform, or only IgII and IgIII, referred to as the beta  isoform. Only the alpha  isoform has been identified for FGF R3 and FGF R4. Additional splicing events for FGF R1‑3, involving the C-terminal half of the IgIII domain encoded by two mutually exclusive alternative exons, generate FGF receptors with alternative IgIII domains (IIIb and IIIc). A IIIa isoform which is a secreted FGF binding protein containing only the N-terminal half of the IgIII domain plus some intron sequences has also been reported for FGF R1. Mutations in FGF R1‑3 have been found in patients with birth defects involving craniosynostosis. The complex patterns of expression of these receptors as well as the specificity of their interactions with the various FGF ligand family members are under investigation.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for FGFR2 Antibody (MAB716)(3)

Publications using MAB716

• DL Coutu, KD Kokkaliari, L Kunz, T Schroeder Multicolor quantitative confocal imaging cytometry Nat. Methods, 2018;15(1):39-46. 2018 [PMID: 29320487] (IHC, Mouse)
• K Nonogaki Treatment with FGFR2-IIIc monoclonal antibody suppresses weight gain and adiposity in KKA(y) mice Nutr Diabetes, 2016;6(11):e233. 2016 [PMID: 27892934] (Neutralization, Mouse)
• Nakayama T, Mutsuga N, Tosato G FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc. Blood, 2006;109(4):1363-72. 2006 [PMID: 17077327] (Neutralization, Mouse)

Bioinformatics

• Gene Symbol: FGFR2